Full Press Release Details
Announces Distribution Agreement with Sports Medicine Supplier Mio-Guard
MD on Exhibit at Mio-Guard Booth #1700 at the
Athletic Trainers' Association (NATA) Expo
N.Y., June 14, 2023 (Business Wire) - NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the
UroShield , PainShield and WoundShield Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced
that it has entered into a distribution agreement with Mio-Guard, LLC ("Mio-Guard") for the sale and distribution of its
PainShield MD product.
Murphy, Chief Executive Officer of NanoVibronix, Inc., commented, "This new distribution agreement is a great opportunity for us
to expand our footprint in sports medicine and within the realm of organized sports teams at various levels. Sports medicine represents
a $5 billion opportunity in the United States and has gained traction in recent years due to the rising incidence of sports injuries
and growing participation in sports and fitness-related activities.1 Mio-Guard provides quality medical supplies to hundreds
of high schools, colleges, clinics and rehab centers across the United States and recognizes the importance of adding an opioid-free
alternative to pain management to its offering of supplies and devices."
the terms of the multi-year agreement, Mio-Guard has the exclusive right to sell and distribute PainShield MD product to its customers
throughout the United States in the areas of athletic team sports and sports medicine. Mio-Guard has placed its first order of PainShield
MD products and will prominently display them next week in Indianapolis at the National Athletic Trainers' Association (NATA) Expo,
the world's largest showcase of products and services for the athletic training profession. Mio-Guard will have a substantial presence
at the event and feature the PainShield MD in Booth #1700 in the Expo Hall.
Zisholz, Chief Executive Officer of Mio-Guard, commented, "This agreement is very exciting for Mio-Guard , the opportunity
to represent this world class product to our customers in the United States is a tremendous one. We are very excited to feature the PainShield
MD at the NATA Expo in Indianapolis next week."
is a national distributor of sports medicine supplies based in Michigan. They have been servicing high schools, colleges, clinics and
rehab centers with quality medical supplies since 1997. Mio-Guard is dedicated to providing quality products at a competitive price providing
exceptional customer service.
Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel,
focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology
allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption
of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of
medical professionals. The Company's primary products include PainShield and UroShield , which are portable devices suitable
for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates,"
"projects," "predicts," "estimates," "aims," "believes,"
"hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance,
are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond
the Company's control, and cannot be predicted or quantified; consequently, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii)
negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv)
intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi)
product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or
inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain
and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare
system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components, (xii) the need
to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be
available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to
additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and
cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv) market and
other conditions. More detailed information about the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including
the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to
read these documents free of charge on the SEC's web site at: http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as
Maas, Managing Principal, Hayden IR, LLC